A randomised, double-blind, placebo-controlled trial of a novel recombinant, humanised, antiinterleukin-13 monoclonal antibody (RPC4046) in patients with active eosinophilic oesophagitis: Results of the heroes study

Authors
Category Primary study
ConferenceUnited European Gastroenterology Journal
Year 2016
This article has no abstract
Epistemonikos ID: 060b9d7393904c55a37c8d9ffcc169dc53ce8676
First added on: Apr 29, 2026